blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1854477

EP1854477 - Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders. [Right-click to bookmark this link]
Former [2007/46]Compositions and methods for treating ophthalmic disorders
[2016/01]
StatusPatent revoked
Status updated on  08.03.2023
Database last updated on 14.09.2024
Most recent event   Tooltip10.03.2023Revocation of patentpublished on 12.04.2023  [2023/15]
Applicant(s)For all designated states
Dyax Corp.
55 Network Drive
Burlington, MA 01803 / US
[2015/40]
Former [2008/40]For all designated states
Dyax Corp.
300 Technology Square
Cambridge, MA 02139 / US
Former [2007/46]For all designated states
Fovea Pharmaceuticals
12 Rue Jean-Antoine de Baif
75013 Paris / FR
Inventor(s)01 / Belichard, Pierre
23 rue de Rome
75008 Paris / FR
 [2007/46]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[N/P]
Former [2016/31]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2014/10]Murphy, Colm Damien
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD / GB
Former [2012/37]Wichmann, Hendrik
Wuesthoff & Wuesthoff Schweigerstrasse 2
81541 München / DE
Former [2008/35]Vossius & Partner
Siebertstrasse 3
81675 München / DE
Former [2007/46]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date07005182.613.03.2007
[2007/46]
Priority number, dateEP2006036000816.03.2006         Original published format: EP 06360008
EP2006029151626.09.2006         Original published format: EP 06291516
[2007/46]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1854477
Date:14.11.2007
Language:EN
[2007/46]
Type: A3 Search report 
No.:EP1854477
Date:11.06.2008
[2008/24]
Type: B1 Patent specification 
No.:EP1854477
Date:03.08.2016
Language:EN
[2016/31]
Type: B9 Corrected patent specification 
No.:EP1854477
Date:14.03.2018
[2018/11]
Search report(s)(Supplementary) European search report - dispatched on:EP15.05.2008
ClassificationIPC:A61K38/55, A61P27/02
[2007/46]
CPC:
A61K38/57 (EP); A61P27/00 (EP); A61P27/02 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/31]
Former [2007/46]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Zusammensetzungen und Verfahren zur Behandlung von Augenerkrankungen[2018/47]
English:Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders.[2016/01]
French:Compositions et procédé de traitement de troubles ophtalmiques[2018/47]
Former [2007/46]Zusammensetzungen und Verfahren zur Behandlung von Augenerkrankungen
Former [2007/46]Compositions and methods for treating ophthalmic disorders
Former [2007/46]Compositions et procédé de traitement de troubles ophtalmiques
Examination procedure05.12.2008Examination requested  [2009/03]
21.01.2009Despatch of a communication from the examining division (Time limit: M06)
30.07.2009Reply to a communication from the examining division
24.11.2014Despatch of a communication from the examining division (Time limit: M06)
04.06.2015Reply to a communication from the examining division
21.01.2016Communication of intention to grant the patent
20.05.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.05.2016Fee for grant paid
20.05.2016Fee for publishing/printing paid
23.06.2016Information about intention to grant a patent
23.06.2016Receipt of the translation of the claim(s)
Divisional application(s)EP11152204.1  / EP2374472
EP18170434.7   Application deemed to be withdrawn  : 02.05.2018
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.01.2009
Opposition(s)Opponent(s)01  03.05.2017  08.05.2017  ADMISSIBLE
Bicycle Therapeutics Limited
Meditrina Building
Babraham Research Campus
Cambridge CB22 3AT / GB
Opponent's representative
Gibson, Mark, et al, et al
Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
 02  03.05.2017  08.05.2017  ADMISSIBLE
Oxurion NV
Gaston Geenslaan 1
3001 Leuven / BE
Opponent's representative
Gevers Patents
De Kleetlaan 7A
1831 Diegem / BE
 [N/P]
Former [2018/46]
Opponent(s)01  03.05.2017  08.05.2017  ADMISSIBLE
Bicycle Therapeutics Limited
Meditrina Building
Babraham Research Campus
Cambridge CB22 3AT / GB
Opponent's representative
Gibson, Mark, et al, et al
Sagittarius IP
Three Globeside
Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ / GB
 02  03.05.2017  08.05.2017  ADMISSIBLE
Oxurion NV
Gaston Geenslaan 1
3001 Leuven / BE
Opponent's representative
Gevers Patents
Intellectual Property House
Holidaystraat 5
1831 Diegem / BE
Former [2018/07]
Opponent(s)01  03.05.2017  08.05.2017  ADMISSIBLE
Bicycle Therapeutics Limited
Meditrina Building
Babraham Research Campus
Cambridge CB22 3AT / GB
Opponent's representative
Gibson, Mark, et al, et al
Sagittarius IP
Three Globeside
Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ / GB
 02  03.05.2017  08.05.2017  ADMISSIBLE
ThromboGenics NV
Gaston Geenslaan 1
3001 Leuven / BE
Opponent's representative
Gevers Patents
Intellectual Property House
Holidaystraat 5
1831 Diegem / BE
Former [2017/24]
Opponent(s)01  03.05.2017  08.05.2017  ADMISSIBLE
Bicycle Therapeutics Limited
Meditrina Building
Babraham Research Campus
Cambridge CB22 3AT / GB
Opponent's representative
Gibson, Mark, et al, et al
Sagittarius IP
Three Globeside
Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ / GB
 02  03.05.2017  08.05.2017  ADMISSIBLE
ThromboGenics NV
Gaston Geenslaan 1
3001 Leuven / BE
Opponent's representative
LC Patents, et al, et al
Kempische Steenweg 542A
3500 Hasselt / BE
20.06.2017Invitation to proprietor to file observations on the notice of opposition
28.12.2017Reply of patent proprietor to notice(s) of opposition
15.10.2018Date of oral proceedings
14.12.2018Despatch of interlocutory decision in opposition
14.12.2018Despatch of minutes of oral proceedings
15.11.2022Legal effect of revocation of patent [2023/15]
01.03.2023Despatch of communication that the patent will be revoked
Appeal following opposition14.02.2019Appeal received No.  T0411/19
24.04.2019Statement of grounds filed
15.11.2022Result of appeal procedure: revocation of the patent
01.03.2023Despatch of the decision of the Board of Appeal
11.02.2019Appeal received No.  T0411/19
04.04.2019Statement of grounds filed
15.11.2022Result of appeal procedure: revocation of the patent
01.03.2023Despatch of the decision of the Board of Appeal
15.11.2022Date of oral proceedings
Fees paidRenewal fee
26.03.2009Renewal fee patent year 03
25.03.2010Renewal fee patent year 04
29.03.2011Renewal fee patent year 05
26.03.2012Renewal fee patent year 06
27.03.2013Renewal fee patent year 07
27.03.2014Renewal fee patent year 08
27.03.2015Renewal fee patent year 09
31.03.2016Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO9521601  (PROTEIN ENG CORP [US], et al) [X] 1-10 * the whole document *;
 [X]US5994125  (MARKLAND WILLIAM [US], et al) [X] 1-10 * column 5, lines 41-64 * * column 11, line 44 - column 12, line 5 * * tables 2,14,27; sequences ID NO. 2-17 *;
 [XY]US6174859  (LEZDEY JOHN [US], et al) [X] 1,2,8-10 * the whole document * [Y] 3-7;
 [X]US2004038893  (LADNER ROBERT C [US], et al) [X] 1-10 * the whole document *;
 [X]US6989369  (LADNER ROBERT CHARLES [US], et al) [X] 1-10 * column 3, line 13 - column 2, line 20 * * column 8, lines 17-41 * * table 3 * * sequence 48 *;
 [X]  - DENNIS MARK S ET AL, "Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, (1995), vol. 270, no. 43, ISSN 0021-9258, pages 25411 - 25417, XP002453532 [X] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.270.43.25411
 [X]  - MA J X ET AL, "Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199611), Database accession no. NLM8950506, XP002476957 [X] 1,2,8-10 * abstract *
 [X]  - MA J-X ET AL, "TREATMENT OF RETINAL EDEMA USING PEPTIDE ANGIOGENIC INHIBITORS", BIOSIS, (2003), XP002330417 [X] 1,2,8-10 * the whole document *
 [Y]  - MA ET AL, "Expression and cellular localization of the kallikrein-kinin system in ocular tissues", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD., LONDON, GB, (1996), vol. 63, ISSN 0014-4835, pages 19 - 26, XP002112528 [Y] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1006/exer.1996.0087
 [Y]  - DOTSENKO VERA ET AL, "Hageman factor and kallikrein in pathogenesis of senile cataracts and the pseudoexfoliation syndrome", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (1996), Database accession no. PREV199699088025, XP002476958 [Y] 1-10 * abstract *
    [ ] - CURRENT EYE RESEARCH NOV 1996, (199611), vol. 15, no. 11, ISSN 0271-3683, pages 1117 - 1123
    [ ] - IMMUNOPHARMACOLOGY, (1996), vol. 32, no. 1-3, ISSN 0162-3109, pages 141 - 145
Examination   - EDWARD P. FEENER, "Plasma Kallikrein and Diabetic Macular Edema", CURRENT DIABETES REPORTS, (20100801), vol. 10, no. 4, doi:10.1007/s11892-010-0127-1, ISSN 1534-4827, pages 270 - 275, XP055153072

DOI:   http://dx.doi.org/10.1007/s11892-010-0127-1
    - J. A. PHIPPS ET AL, "Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor-Stimulated Retinal Vascular Permeability", HYPERTENSION, (20081229), vol. 53, no. 2, doi:10.1161/HYPERTENSIONAHA.108.117663, ISSN 0194-911X, pages 175 - 181, XP055036001

DOI:   http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.117663
by applicantUS38
 US4079
 US4093709
 US4131648
 US4138344
 GB2007091
 US4180646
 US4271143
 US4304767
 US4407792
 EP0171496
 EP0173494
 WO8601533
 EP0184187
 US4615697
 US4816567
 US4946931
 US5041434
 US5968543
 US6010880
 US6057287
 US6087473
 US6333402
 US6413536
 US6596296
 US6613355
 US6667371
 US2005089515
    - BHOOLA et al., Pharmacological Reviews, (19920000), vol. 44, pages 1 - 80
    - ROBERTS et al., Critical Reviews in Eukaryotic Gene Expression, (19950000), vol. 5, pages 385 - 436
    - ENGLES, Am J Health Syst Pharm., (20050000), vol. 62, pages 9 - 14
    - LASKOWSKIKATO, Ann. Rev. Biochem., (19800000), vol. 49, pages 593 - 626
    - PETERSEN et al., Eur. J. Biochem., (19960000), vol. 125, pages 310 - 316
    - WAGNER et al., Biochem. Biophys. Res. Comm., (19920000), vol. 186, pages 1138 - 1145
    - MARKLAND et al., Biochemistry, (19960000), vol. 35, pages 8058 - 8067
    - LEY et al., Mol Divers, (19960000), vol. 2, pages 119 - 124
    - GALLIMORE et al., Thromb Res, (19790000), vol. 16, pages 695 - 703
    - KONDO et al., Endocrinol Jpn., (19840000), vol. 31, pages 635 - 643
    - ZHANG et al., Med Chem., (20060000), vol. 2, pages 545 - 553
OppositionUS5187153
 US5786328
 US2005164928
 WO2006091459
 EP1736465
 US5994125
 US2004038893
 US6989369
 WO2008016883
    - WILLIAMS et al., "DX-88 and HAE: a developmental perspective", Transfusion and Apheresis Science, (20031200), vol. 29, no. 3, pages 255 - 258, XP002605070

DOI:   http://dx.doi.org/10.1016/S1473-0502(03)00170-8
    - XU et al., "Tissue Factor Pathway Inhibitor-2 Is Upregulated by Vascular Endothelial Growth Factor and Suppresses Growth Factor-Induced Proliferation of Endothelial Cells", Arterioscler. Thromb. Vasc. Biol., (20061200), vol. 26, no. 12, pages 2819 - 2825, XP055378935

DOI:   http://dx.doi.org/10.1161/01.ATV.0000248731.55781.87
    - HAN LEE et al., "Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice", Immunol. Letters, (20031031), vol. 89, no. 2-3, pages 155 - 160, XP007920919

DOI:   http://dx.doi.org/10.1016/S0165-2478(03)00130-5
    - DOTSENKO et al., "Hageman factor and kallikrein in pathogenesis of senile cataracts and the pseudoexfoliation syndrome", Immunopharmacol., (19960500), vol. 32, no. 1-3, pages 141 - 145, XP055378942

DOI:   http://dx.doi.org/10.1016/0162-3109(95)00076-3
    - KÜKNER et al., "Effects of intraperitoneal vitamin E, melatonin and aprotinin on leptin expression in the guinea pig eye during experimental uveitis", Acta Ophthalmol. Scand., (20060200), vol. 84, no. 1, pages 54 - 61, XP055378944

DOI:   http://dx.doi.org/10.1111/j.1600-0420.2005.00544.x
    - GAO et al., "Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation", Nature Med, (20070128), vol. 13, pages 181 - 188, XP055379028

DOI:   http://dx.doi.org/10.1038/nm1534
    - KÜKNER et al., "Effects of intraperitoneal vitamin E, melatonin and aprotinin on leptin expression in the guinea pig eye during experimental uveitis", Acta Ophthalmol Scand, (20051208), vol. 84, pages 54 - 61, XP055378944

DOI:   http://dx.doi.org/10.1111/j.1600-0420.2005.00544.x
    - YILMAZ et al., "Aprotinin reduces ischemia-reperfusion injury in the retina of guinea pigs", Eur J Ophthalmol, (20030800), vol. 13, no. 7, pages 642 - 647, XP055379029

DOI:   http://dx.doi.org/10.1177/112067210301300708
    - SCHMIDT B., Klinische Monatsblätter für Augenheilkunde, (19710200), vol. 158, pages 273 - 277, XP055379045
    - MAEDA et al., "THE STRUCTURE AND ACTIVITY OF LEUPEPTINS AND RELATED ANALOGS", J. Antibiot., (19710600), vol. 24, pages 402 - 404, XP055379046

DOI:   http://dx.doi.org/10.7164/antibiotics.24.402
    - MAHDY et al., "Perioperative systemic haemostatic agents", Br J Anaesthesia, (20040726), vol. 93, no. 6, pages 842 - 858, XP055049905

DOI:   http://dx.doi.org/10.1093/bja/aeh227
    - KEDZIERSKA et al., "Plasma Prekallikrein as a Risk Factor for Diabetic Retinopathy", Arch Med Res, (20050900), vol. 36, no. 5, pages 539 - 543, XP027775695
    - ABDOUH et al., "Early upregulation of kinin B1 receptors in retinal microvessels ofthe streptozotocin-diabetic rat", Br J Pharmacol, (20030903), vol. 140, no. 1, pages 33 - 40, XP055379063
    - LAWSON et al., "Enhanced dermal and retinal vascular permeability instreptozotocin-induced type 1 diabetes in Wistar rats: blockadewith a selective bradykinin B1 receptor antagonist", Regul Pept, (20050115), vol. 124, no. 1-3, pages 221 - 224, XP027688988

DOI:   http://dx.doi.org/10.1016/j.regpep.2004.09.002
    - BHOOLA et al., "Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases", Pharmacological Reviews, (19920300), vol. 44, no. 1, pages 1 - 80, XP055379080
    - PINNA et al., "Levels of Human Tissue Kallikrein in the Vitreous Fluid of Patients with Severe Proliferative Diabetic Retinopathy", Ophthalmologica, (20040000), vol. 218, pages 260 - 263, XP055379091

DOI:   http://dx.doi.org/10.1159/000078617
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.